Table 3.
Breast cancer incidence following RRSO and OCS
| Group | Breast cancers/Total* | Breast cancer cases |
RRSO-to-OCS HR (95% CI)‡ | P‡ | |
|---|---|---|---|---|---|
| OCS (n = 1260)† | RRSO (n = 747)† | ||||
| All participants | |||||
| Overall | 88/2007 | 48/1260 | 40/747 | 1.04 (0.64 to 1.68) | .88 |
| All pathogenic BRCA1/2 pathogenic variants | 52/713 | 20/295 | 32/418 | 0.86 (0.45 to 1.67) | .67 |
| BRCA1§ | 37/401 | 16/171 | 21/230 | 0.83 (0.39 to 1.79) | .64 |
| BRCA2§ | 15/310 | 4/123 | 11/187 | 0.98 (0.25 to 3.81) | .98 |
| Noncarriers | 36/1294 | 28/965 | 8/329 | 1.25 (0.64 to 2.44) | .52 |
| Participants with a prior history of breast cancer | |||||
| Overall | 27/775 | 13/422 | 14/353 | 0.62 (0.26 to 1.49) | .28 |
| All BRCA1/2 pathogenic variants | 14/281 | 4/86 | 10/195 | 0.45 (0.13 to 1.56) | .21 |
| BRCA1§ | 8/159 | 3/49 | 5/110 | 0.43 (0.10 to 1.86) | .26 |
| BRCA2§ | 6/121 | 1/36 | 5/85 | 0.42 (0.04 to 4.13) | .45 |
| Noncarriers | 13/494 | 9/336 | 4/158 | 0.80 (0.26 to 2.51) | .71 |
| Participants with no prior history of breast cancer | |||||
| Overall | 61/1232 | 35/838 | 26/394 | 1.33 (0.74 to 2.39) | .34 |
| All BRCA1/2 pathogenic variants | 38/432 | 16/209 | 22/223 | 1.15 (0.52 to 2.54) | .72 |
| BRCA1§ | 29/242 | 13/122 | 16/120 | 1.22 (0.50 to 3.00) | .66 |
| BRCA2§ | 9/189 | 3/87 | 6/102 | 1.09 (0.20 to 6.06) | .92 |
| Noncarriers | 23/800 | 19/629 | 4/171 | 1.56 (0.68 to 3.60) | .29 |
| Premenopausal | |||||
| Overall | 55/1272 | 31/826 | 24/446 | 1.03 (0.56 to 1.89) | .92 |
| All BRCA1/2 pathogenic variants | 37/507 | 17/250 | 20/257 | 0.84 (0.40 to 1.77) | .64 |
| BRCA1§ | 31/298 | 14/151 | 17/147 | 0.84 (0.37 to 1.91) | .68 |
| BRCA2§ | 6/207 | 3/98 | 3/109 | 0.73 (0.11 to 4.82) | .75 |
| Noncarriers | 18/765 | 14/576 | 4/189 | 1.43 (0.56 to 3.67) | .46 |
| Postmenopausal | |||||
| Overall | 33/735 | 17/434 | 16/301 | 1.13 (0.50 to 2.56) | .78 |
| All BRCA1/2 pathogenic variants | 15/206 | 3/45 | 12/161 | 0.97 (0.21 to 4.39) | .97 |
| BRCA1§ | 6/103 | 2/20 | 4/83 | 0.78 (0.09 to 6.80) | .82 |
| BRCA2§ | 9/103 | 1/25 | 8/78 | 1.17 (0.14 to 9.63) | .88 |
| Noncarriers | 18/529 | 14/389 | 4/140 | 1.19 (0.46 to 3.09) | .72 |
*
Participants who underwent risk-reducing mastectomy during prospective follow-up were censored at the time of risk-reducing surgery. HR = hazard ratio; OCS = ovarian cancer screening; RRSO = risk-reducing salpingo-oophorectomy.
†
Numbers reflect the original cohort enrollment.
‡
Based on Cox regression model on age time-scale with RRSO as time-dependent covariate.
§
Two participants with pathogenic variants in both BRCA1 and BRCA2 were excluded.